Vitrafy Life Sciences Ltd

1.460

+0.000

Volume:1.00K

Turnover:1.46K

Market Cap:93.22M

PE:-0.59

High:1.460

Open:1.455

Low:1.455

Close:1.460

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Vitrafy Life Sciences Says US Army Institute Completes Phase One Study of Its Cryopreservation Technology

MT Newswires Live

·

16 Apr

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/VFY.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VFY.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VFY.AU\",,,,,undefined,":{"symbol":"VFY.AU","market":"AU","secType":"STK","nameCN":"Vitrafy Life Sciences Ltd","latestPrice":1.46,"timestamp":1745376728351,"preClose":1.46,"halted":0,"volume":1000,"delay":0,"nameEN":"Vitrafy Life Sciences Ltd","floatShares":34513985,"shares":63849674,"eps":-2.470649,"marketStatus":"Trading","change":0,"latestTime":"04-23 14:07:25 AEST","open":1.455,"high":1.46,"low":1.455,"amount":1459,"amplitude":0.003425,"askPrice":1.46,"askSize":23494,"bidPrice":1.45,"bidSize":900,"shortable":3,"etf":0,"ttmEps":-2.470649,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745388000000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":1.46,"openAndCloseTimeList":[[1745366400000,1745388000000]],"volumeRatio":0.056283,"lotSize":0,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VFY.AU\",,,,,undefined,":{"symbol":"VFY.AU","floatShares":34513985,"roa":"-90.89%","roe":"--","lyrEps":-3.398394,"volumeRatio":0.056283,"shares":63849674,"dividePrice":0,"high":1.46,"amplitude":0.003425,"preClose":1.46,"low":1.455,"week52Low":1.08,"pbRate":"2.69","psRate":"-216.70","week52High":2.1,"institutionHeld":0,"latestPrice":1.46,"committee":-0.926211,"eps":-2.470649,"divideRate":0,"volume":1000,"delay":0,"ttmEps":-2.470649,"open":1.455,"prevYearClose":1.7,"prevWeekClose":1.395,"prevMonthClose":1.2,"prevQuarterClose":1.2,"fiveDayClose":1.23,"twentyDayClose":1.3,"sixtyDayClose":1.735,"earningDate":1745856000000},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/VFY.AU\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VFY.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527376632","title":"Vitrafy Life Sciences Says US Army Institute Completes Phase One Study of Its Cryopreservation Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2527376632","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527376632?lang=en_us&edition=fundamental","pubTime":"2025-04-16 14:36","pubTimestamp":1744785417,"startTime":"0","endTime":"0","summary":"Vitrafy Life Sciences  said that phase one of the blood platelets study undertaken by the US Army Institute of Surgical Research was completed, according to a Wednesday Australian bourse filing.The aim of the study was to complete a fully independent validation study of Vitrafy's cryopreservation technology to determine its ability to cryopreserve blood platelets in commercial unit sizes for use in military and civilian applications.The results generated by the US Army Institute using the technology passed the gating item for continued development under the collaboration-to-commercialization pathway.Platelet samples were collected from eight healthy donors, split into three samples per donor, totaling 24 samples being tested. All cryopreserved samples evaluated using the Vitrafy Cryopreservation Technology, including those with and without cryoprotective agents, resulted in high post-thaw recoveries greater than 88%.Vitrafy and the institute are currently working together to develop th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VFY.AU","BK7048"],"gpt_icon":0},{"id":"2509299505","title":"BUZZ-Australia's Vitrafy Life Sciences hits record low on interim loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2509299505","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509299505?lang=en_us&edition=fundamental","pubTime":"2025-02-06 11:08","pubTimestamp":1738811316,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Vitrafy Life Sciences hits record low on interim loss** Shares of Vitrafy Life Sciences VFY.AX fall 6.6% to a record low of A$1.52** Biomedical firm posts interim loss of A$25.7 mln (","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nL4N3OX06I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","VFY.AU"],"gpt_icon":0},{"id":"2509262386","title":"BRIEF-Vitrafy Life Sciences Posts HY Loss Attributable A$25.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2509262386","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509262386?lang=en_us&edition=fundamental","pubTime":"2025-02-06 09:11","pubTimestamp":1738804300,"startTime":"0","endTime":"0","summary":"BRIEF-Vitrafy Life Sciences Posts HY Loss Attributable A$25.7 MillionFeb 6 (Reuters) - Vitrafy Life Sciences Ltd VFY.AX:HY LOSS ATTRIBUTABLE A$25.7 MILLIONFurther company coverage: VFY.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nFWN3OW230:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","VFY.AU"],"gpt_icon":0},{"id":"2509825148","title":"Vitrafy Life Sciences Ltd - Hy Loss Attributable a$25.7 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2509825148","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509825148?lang=en_us&edition=fundamental","pubTime":"2025-02-06 05:27","pubTimestamp":1738790844,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW230:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7048","VFY.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VFY.AU\",params:#limit:5,,,undefined,":[{"date":"2025-04-29","symbol":"VFY.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1745884800000,"name":null,"time":"","dateTimestamp":1745848800000,"actualEps":null},{"date":"2025-02-06","symbol":"VFY.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1738796400000,"name":null,"time":"","dateTimestamp":1738760400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VFY.AU\",market:\"AU\",,,undefined,":[]}}